Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Sage

8 Analysts Have This to Say About Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Benzinga

North East deals of the week: key acquisitions, investments and contract wins

Companies announcing deals this week include Legal & General, Formula Plastics, Premier Tech, Sage and Hydrock

Birmingham Post

CEO of software giant Sage says economic uncertainty could spur digitisation of smaller firms

Steve Hare said that while inflationary pressures and looming recession weighed on businesses, a counter trend of digitisation was occurring

Birmingham Post

From analysis to the latest developments in health,
read the most diverse news in one place.

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Benzinga

Software giant Sage acquires UK cashflow firm as revenues rise

The North East company has completed its purchase of Futrli which helps firms understand cashflow

Birmingham Post

Software leader Sage becomes official partner of The Hundred in multi-year deal

The partnership follows Sage becoming an official supporter of the Rugby World Cup 2023

Birmingham Post

Analyst Ratings for Sage Therapeutics

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sage Therapeutics: Q1 Earnings Insights

Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

North East deals of the week: contracts, acquisitions and investments

Businesses involved in deals across the region include RSA Insurance, Roman Ltd, Tait Walker and ReViral

Birmingham Post

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining…

Benzinga

Family of victims of Tory Covid care home mistake could be set for £200m

Judges said the Tory Government failed to consider the risks from asymptomatic transmission when they allowed hospital patients to be discharged to care homes

Daily Mirror

Young North East singers offered chance to perform in live BBC Proms concert at Sage Gateshead this summer

Hitting the right note - recruitment drive seeks 16 to 30-year-olds for new choir Voices of the River's Edge to sing in a BBC Proms first

Chronicle Live

Software giant Sage unveils new branding and services to reflect customers' changing needs

Chief executive Steve Hare said the brand refresh 'isn’t just a change of the symbol– it’s a symbol of change' as it seeks to help SMEs as much as possible

Birmingham Post

Sage acquires savings and loan software from MAS Integrated Solutions

Sage says the acquisition supports its drive to help non-profit and faith-based organisations manage programmes that involve a revolving loan fund

Birmingham Post

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Record

Future of Lanarkshire dog track debated by Scottish Parliament committee

We told you earlier this year how 15 dogs died at Shawfield stadium over a three year span

Benzinga

Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Daily Record

Greyhound racing ban call as dogs found drugged with cocaine

An MSP has said he believes it is an industry that is "beyond reform"/

Daily Record

Greyhound racing in Scotland 'beyond reform' as some dogs 'drugged with cocaine'

Campaigners from Scotland Against Greyhound Exploitation (Sage) asked the Scottish Parliament's Rural Affairs, Islands and Natural Environment Committee to call for a complete ban on the sport.

Get all your
news in one place.

100's of premium titles.
One news app.

Manchester Evening News

The fancy pizza oven that's rated as good as Ooni is now £200 cheaper

Shoppers can enjoy massive savings on making the perfect pizza all year round by bringing the effectiveness of a brick pizza oven to their kitchen counter tops

Birmingham Post

Judging panel revealed for CIPD North East of England HR&D Awards

The panel is preparing to carry out the difficult task of choosing the finalists and winners for this year's awards

Benzinga

Expert Ratings For Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:

Birmingham Post

SMEs braced for tough times - but prepared to take hit for Ukraine, survey shows

Poll of small business owners by Newcastle tech firm Sage finds huge levels of solidarity for people in Ukraine

Chronicle Live

Newcastle galleries, museums and attractions urge visitors to 'come back to culture'

Top attractions around Newcastle and Gateshead, from Laing art gallery to Sage Gateshead, are in need of public support as they continue to suffer effects of the pandemic with some losing more than half their visitors

The Independent UK

Living with Covid plan sees Sage stand down regular meetings

Sage is typically activated when an emergency requires science advice at pace, according to the Government.

Benzinga

Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Newcastle City Council

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.